Foundayo is the brand name for orforglipron, an oral GLP1 receptor agonist. It is a once-daily tablet approved for long-term weight reduction in appropriate adults with obesity, or adults with overweight who have at least one weight-related condition, together with a reduced-calorie diet and increased physical activity.
Unlike injectable GLP1 medications, orforglipron is taken by mouth. It provides another evidence-based treatment option for patients who may prefer an oral medication.
An oral GLP1 option
Foundayo provides GLP1 receptor treatment in a once-daily tablet rather than an injection. It is a different active medication from semaglutide and tirzepatide and should not be viewed simply as an injectable medication converted into a pill.
The best choice depends on medical history, treatment goals, expected benefits, side-effect profile, medication preferences, insurance coverage, and ability to follow the medication’s administration instructions.
Foundayo may be considered for adults with obesity, or adults with overweight who have at least one weight-related condition, when prescription medical weight management is appropriate.
A physician should review weight history, medical conditions, current medications, previous weight-management treatment, gastrointestinal history, pregnancy plans, and other safety considerations before prescribing treatment.
Foundayo is taken once daily by mouth. Treatment is started at a lower dose and increased gradually according to the FDA-approved regimen to improve tolerability. Patients should follow the exact instructions on their prescription and medication guide.
The website should not substitute for individualized dosing or pharmacy instructions.
Clinical trials of orforglipron demonstrated clinically meaningful average weight reduction when treatment was combined with reduced-calorie nutrition and increased physical activity. Individual results vary. Starting weight, medical conditions, treatment adherence, tolerability, nutrition, activity, and treatment duration can all affect outcomes.
Our program should avoid guaranteeing a specific amount of weight loss. The goal is meaningful improvement in weight and health through a sustainable medical plan.
The most common side effects are gastrointestinal and may be more noticeable while the dose is being increased. Depending on the patient, these may include:
Persistent, severe, or concerning symptoms should be discussed promptly with the treating clinician.
Important GLP1 safety considerations
Orforglipron has important contraindications, warnings, and precautions that should be reviewed before treatment. Patients should tell their physician about their personal and family medical history, gastrointestinal disease, pancreatic or gallbladder problems, kidney problems, diabetes medications, pregnancy plans, allergies, and all prescription and nonprescription medications.
❇︎ As with other GLP1 receptor agonists, clinically important concerns may include pancreatitis, gallbladder disease, dehydration-related kidney problems, severe gastrointestinal adverse reactions, hypoglycemia when used with certain diabetes medications, and hypersensitivity reactions. The current FDA prescribing information should be used for complete medication-specific warnings and contraindications.
❇︎ Weight-loss medication should not be used during pregnancy. Patients who are pregnant or planning pregnancy should discuss discontinuation and alternative care with their clinician.
Combining GLP1 receptor agonists is generally not part of standard obesity treatment. A patient’s complete medication list should be reviewed before therapy is started, and treatment should follow current FDA labeling and clinical guidance.
Insurance coverage for Foundayo and other anti-obesity medications varies by plan. Some insurance plans cover prescription obesity treatment, some require prior authorization or documentation of specific criteria, and others exclude weight-management medications.
When orforglipron is medically appropriate, our team can help address applicable prior-authorization requirements. Coverage and out-of-pocket cost cannot be guaranteed.
A coverage denial does not mean that medical treatment ends. Your physician can review the reason for denial, determine whether prior authorization or appeal is appropriate, and discuss other evidence-based treatment options based on your medical history, preferences, and coverage.
Obesity is a chronic disease, and weight regain can occur when effective medication is discontinued. Before stopping treatment, it is useful to discuss the reason for discontinuation and develop a long-term maintenance plan. Treatment duration should be individualized based on effectiveness, tolerability, health goals, access, and alternatives.
Yes. Foundayo contains orforglipron, an oral GLP1 receptor agonist.
No. It is an oral medication taken by mouth.
No. Both are oral GLP-1 treatment options, but they contain different active ingredients. Foundayo contains orforglipron; oral Wegovy contains semaglutide.
No. Ozempic contains semaglutide and Zepbound contains tirzepatide. Foundayo contains orforglipron.
Foundayo is taken once daily according to the prescribed regimen.
There is no single best medication for everyone. The decision depends on health history, treatment goals, expected benefits, tolerability, medication preference, coverage, and other clinical factors.
Coverage varies by plan and may require prior authorization. Coverage should be checked for each patient.
This program is designed around FDA-approved prescription treatment options. Treatment is selected after medical evaluation.
An anti-obesity medication may be considered for selected patients after bariatric surgery, but oral medication absorption, anatomy, nutritional status, symptoms, and the prior operation should be considered individually.
Start with a physician-led telemedicine evaluation. We will review your health, goals, treatment history, medication preferences, safety considerations, and insurance coverage to determine the most appropriate next step.
This page is for general educational purposes and does not replace individualized medical advice. Prescription medications have potential benefits, side effects, contraindications, warnings, and drug interactions. Treatment decisions are made after an appropriate medical evaluation. FDA labeling, availability, and insurance coverage may change.
Website content prepared for the Help Obesity Now patient-education site. Medication-specific details should be checked against the current U.S. FDA-approved Foundayo (orforglipron) prescribing information before publication and reviewed periodically as labeling changes.
